標靶蛋白質分解市場規模、佔有率和成長分析：按類型、治療領域、給藥途徑、最終用途和地區分類 - 2025-2032 年行業預測

2023年，標靶蛋白質分解市場規模為64,085萬美元，從2024年的8,1003萬美元成長到2032年的5,27811萬美元，預計複合年成長率為26.40%。

標靶蛋白水解（TPD）作為一種利用小分子選擇性去除有害蛋白質的創新藥物開發策略而備受關注。與傳統方法相比，這種創新方法顯示出顯著的優勢，包括廣泛適用於傳統上被認為「無法治療」的各種涉及蛋白質的疾病。 TPD 的選擇性可最大限度地減少脫靶效應並提高治療效果，同時減少副作用。此外，TPD 藥物具有長效作用，通常可以在很長一段時間內保持其效果，從而有可能減少劑量次數並提高患者的依從性。因此，該領域在開發新治療方法方面具有巨大潛力，特別是對於癌症和遺傳性疾病等複雜疾病，並且被定位為製藥行業的一個有前途的前沿領域。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 宏觀經濟指標
• 價值鏈分析
• 價格分析

標靶蛋白質分解市場規模：按類型

• 市場概況
• 地格羅亞胺
• 免疫調節藥物（IMIDS）
• 蛋白水解靶向嵌合體分子 (PROTACS)
• 突發性視網膜變性症候群（SARDS）
• 選擇性雌激素受體分解劑（SERDS）
• 其他

按治療領域分類的目標蛋白分解市場規模

• 市場概況
• 發炎性疾病
• 神經系統疾病
• 腫瘤性疾病
• 呼吸系統疾病
• 其他

按給藥途徑分類的目標蛋白分解市場規模

• 市場概況
• 口服
• 靜脈
• 其他

目標蛋白分解市場規模：依最終用途分類

• 市場概況
• 製藥和生物技術公司
• 學術研究所
• 醫院和臨床實驗室
• 其他

目標蛋白分解市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Arvinas（USA）
• Kymera Therapeutics（USA）
• Nurix Therapeutics（USA）
• C4 Therapeutics（USA）
• Foghorn Therapeutics（USA）
• Zymeworks（Canada）
• Bristol-Myers Squibb（USA）
• Pfizer（USA）
• AbbVie（USA）
• Sanofi（France）
• Roche（Switzerland）
• AstraZeneca（UK）
• Vertex Pharmaceuticals（USA）
• Amgen（USA）
• Takeda Pharmaceutical（Japan）
• Novartis（Switzerland）
• Gilead Sciences（USA）
• Merck & Co.（USA）
• Janssen Pharmaceuticals（Johnson & Johnson）（USA）
• BeiGene（China）

結論和建議

Targeted Protein Degradation Market size was valued at USD 640.85 Million in 2023 and is poised to grow from USD 810.03 Million in 2024 to USD 5278.11 Million by 2032, growing at a CAGR of 26.40% during the forecast period (2025-2032).

Targeted Protein Degradation (TPD) is gaining traction as a revolutionary drug development strategy, utilizing small molecules to selectively eliminate harmful proteins. This innovative method presents significant advantages over traditional approaches, including its broad applicability to various diseases, including previously deemed "undruggable" proteins. The selectivity of TPD minimizes off-target effects, enhancing therapeutic efficacy while reducing side effects. Moreover, TPD agents demonstrate increased durability, often remaining effective for extended periods, which may lead to less frequent dosing and improved patient adherence. As a result, targeted protein degradation holds immense potential for developing novel treatments, particularly for complex diseases like cancer and genetic disorders, positioning itself as a promising frontier in the pharmaceutical landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Targeted Protein Degradation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Targeted Protein Degradation Market Segmental Analysis

Global Targeted Protein Degradation Market is segmented by type, therapeutic area, route of administration, end use and region. Based on type, the market is segmented into degronimids, immunomodulatory drugs (IMIDS), proteolysis-targeting chimeric molecules (PROTACS), sudden acquired retinal degeneration syndrome (SARDS), selective estrogen receptor degraders (SERDS) and others. Based on therapeutic area, the market is segmented into inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders and others. Based on route of administration, the market is segmented into oral, intravenous and others. Based on end use, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospital & clinical laboratories and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Targeted Protein Degradation Market

The targeted protein degradation market is experiencing significant growth due to the increasing demand for more effective therapies for a range of diseases, particularly cancer, genetic disorders, and autoimmune conditions. There is a pressing need for treatments that address the root causes of these ailments, which heavily impact patient health and overall quality of life. Targeted protein degradation offers the promise of selectively eliminating disease-causing proteins, leading to more effective therapeutic outcomes with reduced side effects. By honing in on proteins implicated in various diseases, this innovative approach opens avenues for developing drugs that can treat previously unmanageable conditions, presenting new hope for patients who lack viable treatment alternatives.

Restraints in the Targeted Protein Degradation Market

The Targeted Protein Degradation market is hindered by inherent complexities that pose significant challenges to growth. This innovative approach necessitates an in-depth understanding of protein structure and function, as well as advanced skills in drug design and development. Creating new therapies in this arena is often a lengthy and intricate endeavor, which can impede progress. Targeted protein degradation aims to create drugs that selectively eliminate harmful proteins within cells by utilizing the body's natural degradation mechanisms, yet achieving this requires detailed knowledge of the disease biology and the implicated proteins. The design of effective, potent, and stable molecules further complicates the development process, demanding substantial investments in research and development.

Market Trends of the Targeted Protein Degradation Market

The targeted protein degradation market is witnessing a significant trend towards the development of oral drug formulations, catering to the demand for more patient-friendly therapies. This shift is largely driven by the need for convenience and improved compliance, as oral medications offer a practical alternative to traditional injection or infusion methods, minimizing the need for hospital visits. Pharmaceutical companies are heavily investing in R&D to create oral drugs that withstand digestive processes while effectively targeting disease pathways. These innovations promise sustained therapeutic effects and enhanced patient adherence, transforming the treatment landscape and elevating standards of patient care in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Targeted Protein Degradation Market Size by Type & CAGR (2025-2032)

• Market Overview
• Degronimids
• Immunomodulatory Drugs (IMIDS)
• Proteolysis-Targeting Chimeric Molecules (PROTACS)
• Sudden Acquired Retinal Degeneration Syndrome (SARDS)
• Selective Estrogen Receptor Degraders (SERDS)
• Others

Global Targeted Protein Degradation Market Size by Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Inflammatory Disorders
• Neurological Disorders
• Oncological Disorders
• Respiratory Disorders
• Others
• Global Targeted Protein Degradation Market Size by Route of Administration & CAGR (2025-2032)
• Market Overview
• Oral
• Intravenous
• Others

Global Targeted Protein Degradation Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospital & Clinical Laboratories
• Others

Global Targeted Protein Degradation Market Size & CAGR (2025-2032)

• North America (Type, Therapeutic Area, Route of Administration, End Use)
  • US
  • Canada
• Europe (Type, Therapeutic Area, Route of Administration, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapeutic Area, Route of Administration, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapeutic Area, Route of Administration, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapeutic Area, Route of Administration, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Arvinas (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nurix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C4 Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foghorn Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (Johnson & Johnson) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations